Kris Gethin's Semax peptide claims, fact-checked

What did @krisgethin actually say?

Gethin promoted Semax, a synthetic peptide, as a nootropic with documented benefits for focus, brain function, and slowing biological aging. He said it has "been studied since the 1940s" in Russia, claimed it has been used by Olympic athletes for performance, and described it as helping with the "prevention of biological aging" caused by overtraining and inflammation. He demonstrated intranasal administration, putting three drops in each nostril, and mentioned it also comes in injectable and capsule forms.

This is a paid partnership post, tagged #CosmicNootropicPartner, which means Gethin is being compensated to say these things. That context matters when evaluating how enthusiastically the evidence is being presented.

Does the science back this up?

Partially. Semax has a real research base, but almost entirely in Russian literature, and the quality of that evidence is far below what the promotional framing implies.

Semax is a heptapeptide analog of ACTH(4-7) developed in Russia at the Institute of Molecular Genetics. It has been studied primarily as a neuroprotective agent in stroke and cognitive impairment contexts. Zozulya et al. (2006, CNS Drug Reviews) reviewed the compound's neurotrophin-modulating effects and noted that it increases BDNF and NGF in rodent models. That is genuinely interesting. However, the human clinical trials are small, mostly conducted in Russia, and have not been replicated in independent Western research settings.

The claim about Olympic use for performance is unverifiable. No published peer-reviewed literature specifically documents Semax use in Olympic athlete cohorts. Gethin presents this as established fact, and it isn't.

What did they get wrong (or right)?

He got the general mechanism directionally right. Semax does appear to interact with BDNF pathways, and there is legitimate interest in peptides as neuroprotective agents. Credit for that.

He got the history wrong. Semax research dates to the 1980s, not the 1940s. The 1940s reference appears to be a mix-up, possibly confusing Semax with broader Soviet peptide research programs. Semax itself was developed much later, with early published work appearing in the late 1980s and early 1990s. Getting a 40-year spread wrong on a compound you're being paid to promote is a meaningful error.

The anti-aging claim is where things get especially shaky. He says Semax helps with the "prevention of biological aging" in athletes. There is no robust human evidence for this specific claim. Oxidative stress and overtraining are real problems, but connecting Semax to measurable anti-aging outcomes in athletes requires a leap the literature does not support. Lopatina et al. (2011, Journal of Molecular Neuroscience) found neuroprotective effects in animal models, but animal models are not athletes, and they are not humans.

He also never mentions that Semax is not FDA-approved, that it sits in a legal gray zone in the United States, and that sourcing and purity from third-party vendors are unverified. That omission matters.

What should you actually know?

Semax is a real compound with a real research profile, but the research is narrow, mostly preclinical or conducted in specific patient populations like stroke recovery, and has not been validated in large-scale, placebo-controlled human trials outside Russia.

The intranasal route Gethin demonstrates does have some pharmacological rationale. Intranasal delivery can allow peptides to bypass the blood-brain barrier via olfactory pathways. Dhuria et al. (2010, Journal of Pharmaceutical Sciences) documented this mechanism for several neuropeptides. So the delivery method is not absurd. But demonstrating a route of administration does not confirm that the compound works for the purposes being claimed.

In the United States, Semax is not approved by the FDA and is not available as a prescription drug. It is sold by vendors like the one tagged in this post as a research compound. Buyers have no regulatory guarantee of purity, potency, or sterility. That is a real risk the video does not address at all.

If you are interested in cognitive support and brain health, there are interventions with substantially more human evidence, including sleep optimization, cardiovascular exercise (Hillman et al., 2008, Nature Reviews Neuroscience), and certain evidence-supported supplements. Semax may eventually earn a stronger evidence base. Right now, the hype is running well ahead of the data.

Bottom line

Semax is not a fraud, but this video presents it as more proven than it is. The historical claim is wrong by decades, the Olympic athlete use claim is unsubstantiated, and the anti-aging framing stretches the available evidence considerably. The paid partnership context adds another reason to apply extra skepticism. Approach this one with real caution before putting anything up your nose based on a sponsored Instagram video.